Cocrystal Pharma (COCP) said Tuesday it plans to extend enrollment in a phase 2a influenza challenge study due to low influenza infection among study participants, making virology results uninterpretable.
The study evaluating Cocrystal's investigational inhibitor CC-42344 has shown no serious adverse events so far, the company said.
Cocrystal Pharma shares were down 32% in recent premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments